PL369566A1 - Stały doustny preparat chlorowodorku tamsulozyny o przedłużonym uwalnianiu i sposób jego wytwarzania - Google Patents

Stały doustny preparat chlorowodorku tamsulozyny o przedłużonym uwalnianiu i sposób jego wytwarzania

Info

Publication number
PL369566A1
PL369566A1 PL369566A PL36956604A PL369566A1 PL 369566 A1 PL369566 A1 PL 369566A1 PL 369566 A PL369566 A PL 369566A PL 36956604 A PL36956604 A PL 36956604A PL 369566 A1 PL369566 A1 PL 369566A1
Authority
PL
Poland
Prior art keywords
dissolution
buffer
tamsulosin hydrochloride
tamsulozine
manufacture
Prior art date
Application number
PL369566A
Other languages
English (en)
Other versions
PL204079B1 (pl
Inventor
Lech Wiąckowki
Wiesław Szelejewski
Andrzej Zaremba
Edyta Pesta-Dynda
Zofia Marchlewska-Cela
Original Assignee
Instytut Farmaceutyczny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instytut Farmaceutyczny filed Critical Instytut Farmaceutyczny
Priority to PL369566A priority Critical patent/PL204079B1/pl
Priority to PL05774341T priority patent/PL1784161T3/pl
Priority to PCT/PL2005/000052 priority patent/WO2006016829A1/en
Priority to SI200530197T priority patent/SI1784161T1/sl
Priority to DE602005004164T priority patent/DE602005004164T2/de
Priority to EP05774341A priority patent/EP1784161B1/en
Priority to AT05774341T priority patent/ATE382332T1/de
Priority to US11/573,562 priority patent/US20070298101A1/en
Publication of PL369566A1 publication Critical patent/PL369566A1/pl
Publication of PL204079B1 publication Critical patent/PL204079B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL369566A 2004-08-12 2004-08-12 Stały doustny preparat chlorowodorku tamsulozyny o przedłużonym uwalnianiu i sposób jego wytwarzania PL204079B1 (pl)

Priority Applications (8)

Application Number Priority Date Filing Date Title
PL369566A PL204079B1 (pl) 2004-08-12 2004-08-12 Stały doustny preparat chlorowodorku tamsulozyny o przedłużonym uwalnianiu i sposób jego wytwarzania
PL05774341T PL1784161T3 (pl) 2004-08-12 2005-08-12 Preparat o kontrolowanym uwalnianiu zawierający chlorowodorek tamsulozyny
PCT/PL2005/000052 WO2006016829A1 (en) 2004-08-12 2005-08-12 Controlled-release formulation comprising tamsulosin hydrochloride
SI200530197T SI1784161T1 (sl) 2004-08-12 2005-08-12 Formulacija s kontroliranim sproščanjem, ki vsebuje tamsulosin hidroklorid
DE602005004164T DE602005004164T2 (de) 2004-08-12 2005-08-12 Formulierung mit kontrollierter freisetzung enthaltend tamsulosin hydrochlorid
EP05774341A EP1784161B1 (en) 2004-08-12 2005-08-12 Controlled-release formulation comprising tamsulosin hydrochloride
AT05774341T ATE382332T1 (de) 2004-08-12 2005-08-12 Formulierung mit kontrollierter freisetzung enthaltend tamsulosin hydrochlorid
US11/573,562 US20070298101A1 (en) 2004-08-12 2005-08-12 Controlled-Release Formulation Comprising Tamsulosin Hydrochloride

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL369566A PL204079B1 (pl) 2004-08-12 2004-08-12 Stały doustny preparat chlorowodorku tamsulozyny o przedłużonym uwalnianiu i sposób jego wytwarzania

Publications (2)

Publication Number Publication Date
PL369566A1 true PL369566A1 (pl) 2006-02-20
PL204079B1 PL204079B1 (pl) 2009-12-31

Family

ID=35445840

Family Applications (2)

Application Number Title Priority Date Filing Date
PL369566A PL204079B1 (pl) 2004-08-12 2004-08-12 Stały doustny preparat chlorowodorku tamsulozyny o przedłużonym uwalnianiu i sposób jego wytwarzania
PL05774341T PL1784161T3 (pl) 2004-08-12 2005-08-12 Preparat o kontrolowanym uwalnianiu zawierający chlorowodorek tamsulozyny

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL05774341T PL1784161T3 (pl) 2004-08-12 2005-08-12 Preparat o kontrolowanym uwalnianiu zawierający chlorowodorek tamsulozyny

Country Status (7)

Country Link
US (1) US20070298101A1 (pl)
EP (1) EP1784161B1 (pl)
AT (1) ATE382332T1 (pl)
DE (1) DE602005004164T2 (pl)
PL (2) PL204079B1 (pl)
SI (1) SI1784161T1 (pl)
WO (1) WO2006016829A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10722458B2 (en) * 2011-12-02 2020-07-28 Pegasus Laboratories, Inc. Amphipathic lipid-based sustained release compositions
JP2015500241A (ja) * 2011-12-02 2015-01-05 ペガサス ラボラトリーズ インコーポレイテッド 両親媒性脂質をベースとする徐放性組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8528195D0 (en) * 1985-11-15 1985-12-18 Boots Co Plc Therapeutic compositions
IT1289160B1 (it) * 1997-01-08 1998-09-29 Jagotec Ag Compressa farmaceutica completamente rivestita per il rilascio controllato di principi attivi che presentano problemi di
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6500457B1 (en) * 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
JP4019374B2 (ja) * 2001-07-27 2007-12-12 アステラス製薬株式会社 口腔内速崩壊錠用徐放性微粒子含有組成物およびその製造法
JP2005512997A (ja) * 2001-11-07 2005-05-12 シントン・ベスローテン・フェンノートシャップ タムスロシン錠

Also Published As

Publication number Publication date
PL1784161T3 (pl) 2008-05-30
WO2006016829A1 (en) 2006-02-16
EP1784161B1 (en) 2008-01-02
DE602005004164D1 (de) 2008-02-14
ATE382332T1 (de) 2008-01-15
PL204079B1 (pl) 2009-12-31
US20070298101A1 (en) 2007-12-27
DE602005004164T2 (de) 2008-12-11
SI1784161T1 (sl) 2008-06-30
EP1784161A1 (en) 2007-05-16

Similar Documents

Publication Publication Date Title
Kranz et al. Development of a single unit extended release formulation for ZK 811 752, a weakly basic drug
TWI469781B (zh) 黏結劑於製造貯存安定性調合物上之用途
US10258584B2 (en) Pregabalin sustained-release preparation
AU2013344281B2 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
ES2642788T3 (es) Fabricación de gránulos sin principio activo y de comprimidos que comprenden los mismos
Liu et al. Zero-order delivery of a highly soluble, low dose drug alfuzosin hydrochloride via gastro-retentive system
US20100247647A1 (en) Sustained release tablets with hydromorphone
US9393205B2 (en) Gastroretentive tablets
KR20110055604A (ko) Ｃｎｓ 장애의 치료 및 예방을 위한 위 체류성 약학적 조성물
EP2352494A1 (en) Novel and potent tapentadol dosage forms
KR20160135373A (ko) 주의력 결핍 장애의 치료를 위한 방법 및 조성물
JP2009538918A (ja) フェニレフリンを含有する徐放薬学的投薬形態
JP2005516946A (ja) ５ｈｔ４部分アゴニスト医薬組成物
TW201334780A (zh) 多西拉敏及吡哆醇及／或其代謝物或鹽之調配物
EP2902016A1 (en) Febuxostat tablet
AU2012326976B2 (en) Sustained-release preparation
KR20230080461A (ko) 약학적 제형
Kranz et al. Development of a multi particulate extended release formulation for ZK 811 752, a weakly basic drug
CA2415154C (en) Modified release formulations of selective serotonin re-uptake inhibitors
US20100003322A1 (en) Enteric coated hydrophobic matrix formulation
US20060182797A1 (en) Sutained release formulation for venlafaxine hydrochloride
PL369566A1 (pl) Stały doustny preparat chlorowodorku tamsulozyny o przedłużonym uwalnianiu i sposób jego wytwarzania
US20150148388A1 (en) Chemical composition
EP3067042A1 (en) Floating system for the treatment of gastric disorders
EP3116500A2 (en) Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms

Legal Events

Date Code Title Description
LAPS Decisions on the lapse of the protection rights

Effective date: 20100812